Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Education
  • Technology
  • Non-profit
  • Arts
  • Senior Living
ncarol.com

Labcorp to Acquire Myriad Autoimmune’s Vectra Testing Business From Myriad Genetics
ncarol.com/10114306

Trending...
  • SPJ's Green Eyeshade Awards Journalism Competition, Celebrating 75 Years, Announces 2025 Honors
  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics' autoimmune business unit, including the Vectra® rheumatoid arthritis (RA) assay. More than one million Vectra tests have been completed since the product's launch in November 2010, and a meaningful portion of testing volume currently flows through Labcorp.

"Labcorp has consistently been a major player in rheumatology and continues to focus on providing medical professionals with the data they need to best treat their RA patients," said Brian Caveney, M.D., chief medical officer and president of Labcorp Diagnostics. "The addition of the Vectra testing capabilities to our in-house products offers tremendous potential for us to expand the test's availability and make Labcorp a single-source diagnostics solution for RA providers. We look forward to welcoming the team to Labcorp."

Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms.

Rheumatoid arthritis, an autoimmune disorder and one of the most common forms of arthritis, causes painful inflammation and tissue damage in the knees, wrists, and other joints. The U.S. Centers for Disease Control and Prevention project that, by 2040, roughly 26% of the country's adult population will be living with doctor-diagnosed arthritis such as RA.

The acquisition of the Vectra test and related IP and other assets complements Labcorp's prior business activity aimed at bolstering its scientific leadership in RA testing and treatment.

More on ncarol.com
  • Rent Like A Champion Acquires CollegeWeekends
  • First Flight Society Celebrates National Aviation Day 2025 on Tuesday, August 19th
  • Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • Free Marketing Book Saves Brands from Being Ignored

The transaction is expected to close by the end of the third quarter, subject to customary closing conditions and regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Specific terms of the transaction were not disclosed. Hogan Lovells acted as legal advisor to Labcorp.

About Labcorp

Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14.0 billion in 2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to the transaction, expected closing timing, projected growth of arthritis in the U.S. population, the anticipated impact of the transaction, and the potential to expand the Vectra test's availability.

Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control, including without limitation, the risk that the transaction may not be completed in a timely manner or at all; the failure to satisfy the conditions to closing the transaction, including the receipt of certain regulatory approvals; the occurrence of any event, change or other circumstance that could give rise to the termination of the transaction agreement; our ability to implement our plans, forecasts and other expectations with respect to the Vectra testing business after completion of the proposed transaction; the impact of the COVID-19 pandemic and its impact on our business and financial condition and on general economic, business, and market conditions; our ability (or inability) to execute on our plans to respond to the COVID-19 pandemic, competitive actions and other unforeseen changes and general uncertainties in the marketplace; changes in government regulations, including health care reform; customer purchasing decisions, including changes in payer regulations or policies; other adverse actions of governmental and third-party payers; changes in testing guidelines or recommendations; federal, state, and local government responses to the COVID-19 pandemic; the effect of public opinion on the company's reputation; adverse results in material litigation matters; the impact of changes in tax laws and regulations; failure to maintain or develop customer relationships; our ability to develop or acquire new products and adapt to technological changes; failure in information technology, systems or data security; adverse weather conditions; the number of revenue days in a financial period; employee relations; personnel costs; and the effect of exchange rate fluctuations. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

More on ncarol.com
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
  • Nonprofit innovator named Mensa Executive Director

The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Ironside HR Named Fastest-Growing Staffing Firm for Second Year
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
  • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
  • Duke Energy announces dividend payments to shareholders
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Financial Educator Nadia Vanderhall Featured On GMA To Share Real-Life Budgeting Insights
  • Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
  • The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
  • Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • Secrets in the Himalayas: Author K.A. Nayampalli Comes to Barnes & Noble Huntersville
  • Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
_catLbl0 _catLbl1

Popular on ncarol.com

  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart - 110
  • Jeopardy!'s Ken Jennings Headlines National Mensa Event - 108
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook - 103
  • Mensa Foundation Prize Awarded to Neuroscientist-Pianist - 103
  • KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly

Similar on ncarol.com

  • Pixel Studio Productions Launches Same-Day Headshots in Houston
  • SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • Nonprofit innovator named Mensa Executive Director
  • Yasmine Roulleau named Managing Director in Vancouver, Canada
  • Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
  • Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute